ASMS 2026: Hybrid DIA/PRM for In-Depth Host Cell Protein Profiling with Relative Quantitation of Problematic Targets
A Johnson & Johnson Innovative Medicine workflow combining DIA global profiling with PRM targeted confirmation, analyzed with Byos
About this Poster
Host cell protein (HCP) analysis sits at the entry point for biotherapeutics moving from lead engineering into manufacturing, and Johnson & Johnson's Cell Engineering and Analytical Sciences group needs workflows that scale across a diverse portfolio of mAbs, multi-specifics, and ADCs. This poster presents a hybrid DIA/PRM acquisition strategy that combines DIA's global profiling reach with PRM's targeted confirmation for problematic high-risk HCPs — analyzed using a vendor-neutral workflow that handles both modes in one pass.
Key Learnings:
- See how a hybrid DIA/PRM workflow achieves comparable proteome coverage to DIA-only while enabling targeted PRM confirmation of selected analytes.
- Compare antibody depletion versus native digestion — antibody depletion gave greater depth of coverage for HCP profiles in this study.
- Understand how heavy-labeled peptides from known high-risk HCPs enable retention-time alignment, MS2 validation, and relative quantitation of the wild-type proteins.
- Learn how the same approach can be applied across studies — for example, evaluating HCP clearance at different purification stages.
Work led by Johnson & Johnson Innovative Medicine (Spring House, PA) in collaboration with Thermo Fisher Scientific (Rockford, IL and San Jose, CA) and Protein Metrics (Boston, MA).